Pierre Canal

Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients.

L. Rostaing, P. Canal, E. Chatelut, 1998, Bulletin du cancer.

Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.

L. Rostaing, J. Izopet, C. Thalamas, 1998, Journal of the American Society of Nephrology : JASN.

Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.

J. Robert, L. Rivory, P. Canal, 1994, Cancer research.

A pharmacokinetic model for alpha interferon administered subcutaneously.

G. Houin, L. Rostaing, J. Izopet, 1999, British journal of clinical pharmacology.

Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.

J. Armand, J. Robert, L. Rivory, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.

S. Guichard, P. Canal, E. Chatelut, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.